Adam Rosenberg
Director/Board Member chez ELIEM THERAPEUTICS, INC.
Fortune : 487 994 $ au 31/03/2024
Profil
Adam J.
Rosenberg was the founder of Link Medicine Corp.
(founded in 2005) where he served as the Chief Executive Officer from 2005 to 2009.
He is also the founder of Teleos Therapeutics LLC.
Mr. Rosenberg's current job(s) include being the Chairman of Ambagon Therapeutics, Inc., an Independent Director at Eliem Therapeutics, Inc., a Director at Sionna Therapeutics, Inc., an Advisor at Atlas Venture Advisors, Inc., and a Venture Partner at RA Capital Management LP (Private Equity).
Mr. Rosenberg's former job includes being the President, Chief Executive Officer & Director of Rodin Therapeutics, Inc. In terms of education, Mr. Rosenberg is a graduate of the University of Virginia and holds an undergraduate degree from Whittier College.
Mr. Rosenberg is also the founder of Teleos Therapeutics LLC.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ELIEM THERAPEUTICS, INC.
0,65% | 18/05/2023 | 178 100 ( 0,65% ) | 487 994 $ | 31/03/2024 |
Postes actifs de Adam Rosenberg
| Sociétés | Poste | Début |
|---|---|---|
| ELIEM THERAPEUTICS, INC. | Director/Board Member | 01/10/2020 |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Director/Board Member | - |
Ambagon Therapeutics, Inc.
 Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | Chairman | - |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | - |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Private Equity Investor | 01/01/2020 |
Anciens postes connus de Adam Rosenberg
| Sociétés | Poste | Fin |
|---|---|---|
Link Medicine Corp.
 Link Medicine Corp. Pharmaceuticals: MajorHealth Technology Link Medicine Corp. develops disease modifying neurodegenerative therapies. The company was founded by Edward I. Rudman, Peter T. Lansbury, David Neafus and Adam J. Rosenberg in 2005 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01/01/2009 |
| Teleos Therapeutics LLC | Chief Executive Officer | - |
Rodin Therapeutics, Inc.
 Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Chief Executive Officer | - |
Formation de Adam Rosenberg
| University of Virginia | Graduate Degree |
| Whittier College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ELIEM THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Link Medicine Corp.
Link Medicine Corp. Pharmaceuticals: MajorHealth Technology Link Medicine Corp. develops disease modifying neurodegenerative therapies. The company was founded by Edward I. Rudman, Peter T. Lansbury, David Neafus and Adam J. Rosenberg in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Rodin Therapeutics, Inc.
Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Health Technology |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Ambagon Therapeutics, Inc.
Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | Health Technology |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Health Services |
| Teleos Therapeutics LLC |
